GURUFOCUS.COM » STOCK LIST » USA » OTCPK » THC Therapeutics Inc (OTCPK:THCT) » Definitions » Debt-to-EBITDA
Switch to:

THC Therapeutics (OTCPK:THCT) Debt-to-EBITDA

: 0.59 (As of Jul. 2022)
View and export this data going back to 2007. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

THC Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2022 was $0.80 Mil. THC Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2022 was $0.00 Mil. THC Therapeutics's annualized EBITDA for the quarter that ended in Jul. 2022 was $1.36 Mil. THC Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2022 was 0.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for THC Therapeutics's Debt-to-EBITDA or its related term are showing as below:

THCT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.62   Med: -0.3   Max: 0.45
Current: -0.59

During the past 13 years, the highest Debt-to-EBITDA Ratio of THC Therapeutics was 0.45. The lowest was -0.62. And the median was -0.30.

THCT's Debt-to-EBITDA is ranked worse than
100% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.65 vs THCT: -0.59

THC Therapeutics (OTCPK:THCT) Debt-to-EBITDA Historical Data

The historical data trend for THC Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

THC Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.01 -0.30 -0.58 -0.57

THC Therapeutics Quarterly Data
Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.44 -0.29 -0.34 0.59

THC Therapeutics (OTCPK:THCT) Debt-to-EBITDA Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, THC Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

THC Therapeutics (OTCPK:THCT) Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, THC Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where THC Therapeutics's Debt-to-EBITDA falls into.



THC Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

THC Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Jul. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.801 + 0) / -1.406
=-0.57

THC Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.801 + 0) / 1.364
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jul. 2022) EBITDA data.


THC Therapeutics  (OTCPK:THCT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


THC Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of THC Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


THC Therapeutics (OTCPK:THCT) Business Description

THC Therapeutics logo
Traded in Other Exchanges
N/A
Address
11700 W Charleston Bpulevard, Suite 73, Las Vegas, NV, USA, 89135
THC Therapeutics Inc is a United States-based company. It is focused on developing dHydronator, a sanitizing herb dryer. The main function of the dHydronator is to accelerate the drying time of an herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis. It will reduce the drying time for cannabis from 10-14 days down to less than 14 hours while reducing the viability of microbial contaminants.
Executives
Tanaka Hiro director, officer: Vice President 3RD FLOOR, 207 REGENT STREET LONDON X0 W1B 3HH
Smith Adrian J R director, officer: Chair of the Board 119 SPRINGLINE DRIVE VERO BEACH FL 32963
Mann Jamie director, 10 percent owner, officer: CEO, CFO 3RD FLOOR, 207 REGENT STREET LONDON X0 W1B 3HH
Ho Eden director, officer: CEO 701 XUANG MI HU ROAD, XI YUAN, FUTIAN SHENZHEN F4 XXXXXX
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership